Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with A
| Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
|---|---|---|---|---|---|---|---|
| Q3 2024 | ALLANTOIN | VAGINAL | CREAM | 2.00 %w/w | Deletion | ||
| Q2 2024 | ACETIC ACID | INTRAMUSCULAR | INJECTION | 0.35 %w/v | MDE Replacement | ||
| Q3 2024 | ACETIC ACID | INTRAMUSCULAR | INJECTION | 22mg | MDE Replacement | ||
| Q2 2024 | ACETIC ACID | SUBCUTANEOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | ADJ PH | MDE Replacement | ||
| Q3 2024 | ACETIC ACID | SUBCUTANEOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 32mg | MDE Replacement | ||
| Q2 2024 | ACETYLTRIBUTYL CITRATE | ORAL | CAPSULE, DELAYED RELEASE | 7.60 mg | MDE Replacement | ||
| Q3 2024 | ACETYLTRIBUTYL CITRATE | ORAL | CAPSULE, DELAYED RELEASE | 122mg | MDE Replacement | ||
| Q2 2024 | ALCOHOL | TRANSDERMAL | GEL, METERED | 73.50 %w/w | MDE Replacement | ||
| Q3 2024 | ALCOHOL | TRANSDERMAL | GEL, METERED | 525mg | MDE Replacement | ||
| Q2 2024 | ANHYDROUS CITRIC ACID | INTRAVENOUS | INJECTION, POWDER, FOR SOLUTION | 41.50 mg | MDE Replacement | ||
| Q3 2024 | ANHYDROUS CITRIC ACID | INTRAVENOUS | INJECTION, POWDER, FOR SOLUTION | 35mg | MDE Replacement | ||
| Q2 2024 | ARGININE | INTRAVENOUS | INJECTION, POWDER, FOR SOLUTION | 780.00 mg | MDE Replacement | ||
| Q3 2024 | ARGININE | INTRAVENOUS | INJECTION, POWDER, FOR SOLUTION | 3600mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections: IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: July 3, 2024
Database Last Updated: July 31, 2024